Home Stock

Stock Research: Novozymes

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Novozymes

CPH:NSIS B DK0060336014
65
  • Value
    6
  • Growth
    87
  • Safety
    Safety
    84
  • Combined
    73
  • Sentiment
    42
  • 360° View
    360° View
    65
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Novozymes A/S is a biotechnology company that produces and sells industrial enzymes, microorganisms, and biopharmaceutical ingredients. It operates in agriculture, bioenergy, food & beverages, household care, and more. The company's main regions are Europe, Middle East & Africa, North America, Asia Pacific, and Latin America. In the last fiscal year, the company had a market cap of $32,679 million, profits of $1,873 million, revenue of $3,969 million, and 10,582 employees.

more

ANALYSIS: With an Obermatt 360° View of 65 (better than 65% compared with alternatives), overall professional sentiment and financial characteristics for the stock Novozymes are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Novozymes. The consolidated Growth Rank has a good rank of 87, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 87% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 84 which means that the company has a financing structure that is safer than 84% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 6 which means that the share price of Novozymes is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 94% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 42, which means that professional investors are more pessimistic about the stock than for 58% of alternative investment opportunities. ...read more

more
Strongest Rank Price vs. Sales (P/S)
Weakest Rank Liquidity
Country Denmark
Industry Specialty Chemicals
Size X-Large
Website novozymes.com
Index
OMX C20
Renewables Users
Novozymes stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
6 6 3 3
Growth
87 92 45 21
Safety
Safety
84 46 62 68
Sentiment
42 80 100 83
360° View
360° View
65 60 59 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 56 56 1
Opinions Change
50 41 87 50
Pro Holdings
n/a 60 100 83
Market Pulse
23 84 93 98
Sentiment
42 80 100 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
6 6 3 3
Growth
87 92 45 21
Safety Safety
84 46 62 68
Combined
73 51 20 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
3 3 5 7
Price vs. Earnings (P/E)
5 7 5 1
Price vs. Book (P/B)
19 16 1 1
Dividend Yield
35 33 40 44
Value
6 6 3 3
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
78 87 60 42
Profit Growth
83 73 57 23
Capital Growth
82 73 11 31
Stock Returns
35 65 65 71
Growth
87 92 45 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
76 44 59 77
Refinancing
16 8 14 8
Liquidity
92 90 100 90
Safety Safety
84 46 62 68

Similar Stocks

Discover high‑ranked alternatives to Novozymes and broaden your portfolio horizons.

Strabag

VIE:STR
Country: Austria
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Arkema

PAR:AKE
Country: France
Industry: Specialty Chemicals
Size: X-Large
Full Stock Analysis

Michelin

PAR:ML
Country: France
Industry: Tires & Rubber
Size: X-Large
Full Stock Analysis

Yara International

OSL:YAR
Country: Norway
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews